• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.

    8/14/25 11:44:47 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EWTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    EDGEWISE THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    28036F105

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    28036F105


    1Names of Reporting Persons

    JANUS HENDERSON GROUP PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,503,349.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,503,349.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,503,349.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA, HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    EDGEWISE THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    1715 38TH ST BOULDER, CO 80301
    Item 2. 
    (a)Name of person filing:

    Janus Henderson Group plc
    (b)Address or principal business office or, if none, residence:

    201 Bishopsgate EC2M 3AE, United Kingdom
    (c)Citizenship:

    Y9
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    28036F105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    JHIUS may be deemed to be the beneficial owner of 5,437,423 shares
    (b)Percent of class:

    5.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    5437423

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    5437423

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    N/A
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries of Janus Henderson and are registered investment advisers furnishing investment advice to Managed Portfolios.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    N/A
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    N/A

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JANUS HENDERSON GROUP PLC
     
    Signature:Kristin Mariani
    Name/Title:Head of North America Compliance, CCO
    Date:08/14/2025
    Exhibit Information

    POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

    Get the next $EWTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EWTX

    DatePrice TargetRatingAnalyst
    9/25/2025$20.00Neutral
    Goldman
    7/30/2025$46.00Strong Buy
    Raymond James
    6/30/2025$42.00Buy
    H.C. Wainwright
    4/30/2025$41.00Buy
    Guggenheim
    4/2/2025$14.00Sector Outperform → Sector Perform
    Scotiabank
    3/7/2025$50.00Sector Outperform
    Scotiabank
    1/22/2025$30.00Hold
    Stifel
    11/22/2024$45.00Outperform
    Evercore ISI
    More analyst ratings

    $EWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Russell Alan J exercised 100,000 shares at a strike of $0.18 and sold $2,112,450 worth of shares (100,000 units at $21.12) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:06:38 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:04:59 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Nofi Michael

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:03:07 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    SEC Filings

    View All

    Edgewise Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

    11/10/25 5:17:53 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Edgewise Therapeutics Inc.

    10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)

    11/6/25 8:05:35 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)

    11/6/25 8:00:47 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:04:59 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:42:30 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:33:31 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

    BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 10, 2025, Edgewise granted an inducement stock option to purchase a total of 262,500 shares of Edgewise's common stock and an award of inducement restricted stock units ("RSU award") covering a total of 43,750 shares of Edgewise's common stock to Michael Nofi, in connection with the commencement of his employment as Chief Financial Officer of the Company, effective today, pursuant to Edgewise's 2024 Induce

    11/12/25 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

    BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. "As we enter a pivotal stage in our Company's evolution, we a

    11/10/25 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics to Participate in Upcoming Investor Conferences

    BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside chat: Tuesday, November 11, 2025 at 8:30 am ET Piper Sandler 37th Annual Healthcare ConferenceFireside chat: Tuesday, December 2, 2025 at 2 pm ET 8th Annual Evercore Healthcare ConferenceFireside chat: Wednesday, December 3, 2025 at 3:25 pm ET The webcasts can be found on the Edgewise Event

    11/7/25 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Edgewise Therapeutics with a new price target

    Goldman initiated coverage of Edgewise Therapeutics with a rating of Neutral and set a new price target of $20.00

    9/25/25 8:29:56 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Edgewise Therapeutics with a new price target

    Raymond James initiated coverage of Edgewise Therapeutics with a rating of Strong Buy and set a new price target of $46.00

    7/30/25 7:32:57 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Edgewise Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $42.00

    6/30/25 8:01:12 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Financials

    Live finance-specific insights

    View All

    Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

    – Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos

    9/11/22 5:00:00 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

    – EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month

    6/20/22 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

    - Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi

    6/16/22 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Leadership Updates

    Live Leadership Updates

    View All

    Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

    BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. "As we enter a pivotal stage in our Company's evolution, we a

    11/10/25 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

    Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin

    5/7/24 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors

    – President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos

    3/6/23 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 6:22:11 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 4:31:39 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Edgewise Therapeutics Inc.

    SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 4:14:38 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care